Vanguard Group Inc boosted its position in shares of Scholar Rock Holding Corp (NASDAQ:SRRK) by 479.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 231,656 shares of the company’s stock after acquiring an additional 191,656 shares during the period. Vanguard Group Inc owned 0.92% of Scholar Rock worth $5,966,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Redmile Group LLC raised its stake in Scholar Rock by 1.3% during the 3rd quarter. Redmile Group LLC now owns 1,773,107 shares of the company’s stock worth $45,658,000 after acquiring an additional 22,699 shares during the period. BlackRock Inc. purchased a new stake in Scholar Rock during the 3rd quarter valued at approximately $9,485,000. Sphera Funds Management LTD. grew its holdings in Scholar Rock by 4.5% during the 3rd quarter. Sphera Funds Management LTD. now owns 296,856 shares of the company’s stock valued at $7,644,000 after buying an additional 12,859 shares in the last quarter. Vanguard Group Inc. grew its holdings in Scholar Rock by 479.1% during the 3rd quarter. Vanguard Group Inc. now owns 231,656 shares of the company’s stock valued at $5,966,000 after buying an additional 191,656 shares in the last quarter. Finally, BB Biotech AG purchased a new stake in Scholar Rock during the 3rd quarter valued at approximately $4,891,000. Institutional investors own 50.78% of the company’s stock.

Shares of SRRK stock traded up $0.09 on Monday, reaching $16.60. The company’s stock had a trading volume of 436 shares, compared to its average volume of 71,437. Scholar Rock Holding Corp has a 1 year low of $13.09 and a 1 year high of $30.00.

SRRK has been the subject of a number of research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $25.00 price objective on shares of Scholar Rock in a report on Friday, November 9th. Cowen reaffirmed a “buy” rating on shares of Scholar Rock in a report on Monday, November 12th. Finally, Zacks Investment Research raised shares of Scholar Rock from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Friday, November 16th. Five analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $26.75.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2019/02/11/scholar-rock-holding-corp-srrk-holdings-raised-by-vanguard-group-inc.html.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of various medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company is developing its lead antibody product candidate, SRK-015, a first-in-class inhibitor of the activation of myostatin that is in clinical development stage for the treatment of spinal muscular atrophy.

Featured Story: Day Trading

Want to see what other hedge funds are holding SRRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Scholar Rock Holding Corp (NASDAQ:SRRK).

Institutional Ownership by Quarter for Scholar Rock (NASDAQ:SRRK)

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.